Novamind Announces Strategic Investment in Bionomics to Support PTSD Clinical Trial londonmercury.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from londonmercury.com Daily Mail and Mail on Sunday newspapers.
$16 Million Capital Raise to Progress Bionomics BNC210 PTSD Trial
News provided by
Share this article
Significant participation from North American and European institutional and sophisticated investors
This capital raising enables proceeding with the Phase 2b PTSD trial in mid-2021 as planned and sees the Company well capitalised
ADELAIDE, Australia, Feb. 10, 2021 /PRNewswire/ Bionomics Limited (ASX: BNO,OTCQB: BNOEF, Germany: AU000000BNO5), a global, clinical stage biopharmaceutical company, is pleased to announce that it has entered into placement agreements with a number of North American and European institutional and sophisticated investors, to raise A$15,991,634. The Company used its 15% placement capacity under Listing Rule 7.1 of 110,287,132 shares.